Combinations of 2'-C-Methylcytidine Analogues with Interferon-α2b and Triple Combination with Ribavirin in the Hepatitis C Virus Replicon System

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antiviral Chemistry & Chemotherapy

• Publication date

  2008-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/095632020801900104PMID 18610555PMCID PMC2742417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus.

  2007cited by this paper
• Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.

  2007cited by this paper
• Nucleoside Analog Inhibitors of Hepatitis C Virus Replication

  2006cited by this paper
• Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′-C-Methylcytidine, the Active Component of Valopicitabine

  2006influential reference
• Peginterferon alpha‐2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha‐2b

  2006cited by this paper
• 736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trial

  2006cited by this paper
• Inhibition of Hepatitis C Replicon RNA Synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication

  2006cited by this paper
• Nucleoside analog inhibitors of hepatitis C virus replication.

  2006cited by this paper
• Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

  2006cited by this paper
• Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

  2006cited by this paper
• Novel approaches for therapy of chronic hepatitis C.

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Mechanism of action of interferon and ribavirin in treatment of hepatitis C

  2005cited by this paper
• Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.

  2005cited by this paper
• NM 283, AN EFFICIENT PRODRUG OF THE POTENT ANTI-HCV AGENT 2′-C-METHYLCYTIDINE

  2005cited by this paper
• Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.

  2004cited by this paper
• Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.

  2004cited by this paper
• Ribavirin Treatment Up-Regulates Antiviral Gene Expression via the Interferon-Stimulated Response Element in Respiratory Syncytial Virus-Infected Epithelial Cells

  2003cited by this paper
• Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture

  2003cited by this paper
• Cytopathic and Noncytopathic Interferon Responses in Cells Expressing Hepatitis C Virus Subgenomic Replicons

  2003cited by this paper
• Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons

  2003cited by this paper
• Efficient initiation of HCV RNA replication in cell culture.

  2000influential reference
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Multiple drug effect analysis with confidence interval.

  1994cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Nucleoside Antiviral Agents for HCV

  2020cites this paper
• Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice

  2019cites this paper
• Cell-line dependent antiviral activity of sofosbuvir against Zika virus.

  2017cites this paper
• Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.

  2017cites this paper
• Inhibitory effects of Pycnogenol® on hepatitis C virus replication.

  2015cites this paper
• In Vitro Drug Combination Studies of Letermovir (AIC246, MK-8228) with Approved Anti-Human Cytomegalovirus (HCMV) and Anti-HIV Compounds in Inhibition of HCMV and HIV Replication

  2015cites this paper
• Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection

  2015cites this paper
• Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.

  2014cites this paper
• Chutes and ladders in hepatitis C nucleoside drug development.

  2014cites this paper
• Intracellular Effects of the Hepatitis C Virus Nucleoside Polymerase Inhibitor RO5855 (Mericitabine Parent) and Ribavirin in Combination

  2014cites this paper
• Use of 2'-spirocyclic ethers in HCV nucleoside design.

  2014cites this paper
• Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals.

  2013cites this paper
• RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.

  2013cites this paper
• Green Tea Phenolic Epicatechins Inhibit Hepatitis C Virus Replication via Cycloxygenase-2 and Attenuate Virus-Induced Inflammation

  2013cites this paper
• Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds

  2013cites this paper
• Anti‐hepatitis C virus activity of 3‐hydroxy caruilignan C from Swietenia macrophylla stems

  2012cites this paper
• Treating Chronic HCV Without Interferon and/or Ribavirin

  2012cites this paper
• Future perspectives: towards interferon-free regimens for HCV.

  2012cites this paper
• San‐Huang‐Xie‐Xin‐Tang extract suppresses hepatitis C virus replication and virus‐induced cyclooxygenase‐2 expression

  2011cites this paper
• Antiviral drugs against hepatitis C virus

  2011cites this paper
• An in vitro coupled transcription/translation reporter system for hepatitis C virus RNA-dependent RNA polymerase.

  2011cites this paper
• Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.

  2011cites this paper
• Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2.

  2011cites this paper
• Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.

  2010cites this paper
• A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase.

  2010cites this paper
• Discovery of a highly synergistic anthelmintic combination that shows mutual hypersusceptibility

  2010cites this paper
• Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome

  2010cites this paper
• Pseudo-peptides derived from isomannide: inhibitors of serine proteases

  2010cites this paper
• New NS5B polymerase inhibitors for hepatitis C

  2010cites this paper
• HCV drug discovery aimed at viral eradication

  2010cites this paper
• Cellular models for the screening and development of anti-hepatitis C virus agents.

  2009cites this paper
• Pseudo-peptides Derived from Isomannide: Inhibitors of Serine Proteases

  2008cites this paper